Tag: checkpoint inhibitors
-
Immunotherapy Advances in SCLC: Promise, Limitations, and the Biomarker Gap
Immunotherapy Advances in Small Cell Lung Cancer (SCLC): A Quiet but Persistent Shift Small cell lung cancer has long challenged clinicians with its aggressive biology and historically limited treatment options. In recent years, immunotherapy has emerged as a meaningful, if nuanced, addition to the standard of care. The story is not a single triumph but…
-
Myeloid-Driven Immunotherapy Resistance in Kidney Cancer: Interferon Signaling Under Scrutiny
Overview: A New Mechanism Behind Immunotherapy Resistance in Kidney Cancer Immunotherapy has transformed the treatment landscape for advanced renal cell carcinoma (RCC), but responses remain inconsistent. A landmark study published in Immunity (October 2025) by researchers including Dana-Farber Cancer Institute’s Eliezer M. Van Allen, MD, identifies a critical role for myeloid cells in shaping resistance…
-
Nanoparticle Breakthrough: A New Strategy to Activate the Immune System Against Ovarian Tumors
New Nanoparticles Spark Immune Response Against Ovarian Tumors Researchers are turning to nanotechnology to overcome a long-standing challenge in cancer immunotherapy: how to effectively stimulate the immune system to recognize and destroy ovarian tumors. A new class of nanoparticles is showing promise by delivering immune-activating signals directly to tumor sites and modulating the tumor microenvironment…
-
Switching Immune-Cold Tumors to Immune-Hot: A Breakthrough Path to Durable Cancer Immunity
Turning the Tide on Immune-Cold Tumors In a pivotal study published in Nature Immunology, scientists reveal a strategy that could make aggressive, immune-suppressive tumors more vulnerable to the body’s defenses. Funded by the National Cancer Institute/NIH, the research builds on prior work in breast cancer to show that transforming the tumor microenvironment can awaken a…
-
Switching Immune Cold Tumors to Immune Hot: A Breakthrough in Cancer immunotherapy
Overview: Turning immune-cold tumors into immune-hot targets In a significant advance for cancer immunotherapy, researchers have identified a strategy to reprogram immune-cold tumors—those that typically evade detection—into immune-hot tumors that recruit and coordinate immune cells to attack cancer. The study, recently published in Nature Immunology, builds on decades of work to harness the body’s own…
-
Researchers Discover a Switch that Transforms Immune-Cold Tumors into Immune-Hot, Boosting Cancer Therapy
Transforming Immune-Cold Tumors into Immune-Active Targets Cancer research has long grappled with tumors that evade the body’s defenses. A recent study published in Nature Immunology, backed by the National Cancer Institute/NIH, reports a promising strategy to convert these immune-cold tumors into immune-hot ones. By priming the tumor environment with immune-activating signals, researchers observed a robust,…
-
Checkpoint inhibitors reveal tissue repair role, offering hope for chronic wounds
Unveiling a new function for a familiar immune brake Checkpoint inhibitors are well known for their role in cancer therapy, where they release the immune system’s brakes to attack tumor cells. In a surprising twist, researchers from the University of Zurich (UZH) have uncovered a second, equally important function: TIGIT, a checkpoint protein, promotes tissue…